Clinical Trials in China / NCT06459934
Recruiting
Observational
Clinical Outcomes of Cardiovascular Disease
NCT06459934 · tracked via the Priya Life Science China tracker
Condition(s) studied
Cardiovascular DiseasesHeart FailureCoronary Artery Disease
Study summary
This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Evaluate multiple examination indicators of patients at baseline, 1 year and longer, and follow up on the incidence of major cardiovascular and cerebrovascular adverse events, heart failure readmission, death, and other endpoint events.
Eligibility
Inclusion Criteria:
1. Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%.
2. Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and/or the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs.
3. Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure.
4. Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.
5. Able to sign informed consent form.
Exclusion Criteria:
1. Age\<18 years old, or\>80 years old.
2. Patients with various malignant tumors.
3. Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit).
4. Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit).
5. Those who have participated in other clinical studies within the past three months.
6. Individuals without legal capacity or with limited legal capacity.
7. Any situation where the researcher deems it unsuitable to participate in the clinical study.
Primary outcome measure(s)
- All cause death — 1 year.
Death caused by various reasons. - Cardiac death — 1 year.
Death caused by cardiac reasons. - Main adverse cardiovascular events（MACE） — 1 year.
The composite endpoint for hospitalization for heart failure, non fatal myocardial infarction, and cardiac death. - Heart failure — 1 year.
Heart failure (HF) is defined according to the diagnostic criteria for HF. Briefly, HF was defined as typical signs and symptoms of HF (NYHA class III or IV), as well as a history of myocardial infarct (MI) or with advanced coronary artery disease including severe 3-vessel disease and chronic total occlusion or other Organic heart disease. - Stroke — 1 year.
Stroke was defined as a sudden onset of vertigo, numbness, aphasia, or dysarthria caused by cerebrovascular disease, including hemorrhage, embolism, thrombosis, or aneurysm rupture, and persisting for \> 24 hours
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Xinjiang Medicial University | Ürümqi | Xinjiang | Recruiting |
More Xinjiang Medical University trials in China
Other trials for the same condition
Cohort Study of Chronic Heart Failure
Recruiting
IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06459934 on ClinicalTrials.gov ↗ ← All trials in China